LBS Business Summary

Lin BioScience, Inc. (6696.TWO), commonly referred to as LBS, is a Taipei-based clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, milestone payments, and R&D service fees, largely driven by its majority-owned subsidiary, Belite Bio (NASDAQ: BLTE). The company’s business is segmented into three core therapeutic areas: ophthalmology, oncology, and metabolic diseases. Its flagship asset, Tinlarebant (LBS-008), is a first-in-class oral therapy targeting Stargardt disease and dry age-related macular degeneration (Dry AMD), currently in global Phase 3 clinical trials. Other key pipeline candidates include LBS-007, a CDC7 inhibitor for acute leukemia, and LBS-002, an anti-tubulin agent for brain tumors. Lin BioScience competes globally with major players such as Apellis Pharmaceuticals, Astellas Pharma (via Iveric Bio), and Alkeus Pharmaceuticals, positioning itself as a high-growth innovator focused on orphan drug designations and breakthrough therapies for unmet medical needs. The company was founded by Chairman Dr. Yu-Hsin (Tom) Lin and is currently led by CEO Dr. Zhengqi Wang and Chief Scientific Officer Dr. Nathan Mata. Dr. Lin, a former executive at Pfizer and Novartis, holds a Ph.D. from the University of Sydney and an MBA from Johns Hopkins University, providing the firm with deep institutional knowledge of global pharmaceutical markets. Dr. Wang brings extensive expertise in drug development and regulatory strategy, while Dr. Mata leads the scientific innovation behind the company's RBP4 and CDC7 platforms. The leadership team is supported by a board of directors featuring prominent figures from Taiwan’s financial and biotech sectors, while the investor base includes significant institutional holdings from healthcare-focused venture capital firms. This leadership structure has successfully secured multiple U.S. FDA Fast Track and Orphan Drug designations, leveraging a "hub-and-spoke" model to maximize the commercial potential of their intellectual property through subsidiaries like Belite Bio.